Agnieszka Wilkos-Kuc
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Agnieszka Wilkos-Kuc has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Tomasz Żarnowski
Department of Diagnostic and Microsurgery of Glaucoma, Medical University of Lublin, Chmielna 1 Street, 20-079 Lublin, Poland
2 shared publications - Agnieszka Rozegnał-Madej
Department of Diagnostics and Microsurgery of Glaucoma, Medical University, 20-079 Lublin, Poland
1 shared publication - Aleksandra Wlaź
Department of Diagnostics and Microsurgery of Glaucoma, Medical University, Lublin, Poland
1 shared publication - Anna Kuna
Department of Diagnostics and Microsurgery of Glaucoma, Medical University, Chmielna 1, 20-079 Lublin, Poland
1 shared publication - Ewa Kosior-Jarecka
Department of Diagnostics and Microsurgery of Glaucoma, Medical University of Lublin, 20-079 Lublin, Poland
1 shared publication - Olga Majkowska1 shared publication
Latest Publications
- Open Access
- 29 October 2025
- Published by Termedia Sp. z.o.o. in Ophthalmology
- Vol. 28 (2) , 36-40
Neovascular glaucoma
Neovascular glaucoma is an aggressive form of secondary angle-closure glaucoma that can potentially lead to blindness. It is characterized by neovascularization of the iris and the drainage angle. The proliferation of fibrovascular tissue within the drainage angle leads to the formation of peripheral anterior synechiae and an increase in intraocular pressure. Neovascular glaucoma develops as a consequence of ischemia and hypoxia in the posterior segment of the eye. The ischemic retina produces pro-angiogenic factors. The most important factor in the process of neovascularization is vascular endothelial growth factor. The most common underlying causes of neovascular glaucoma are diabetic retinopathy, central retinal vein occlusion, and ocular ischemic syndrome. The course of neovascular glaucoma can be divided into four stages: pre-rubeosis stage, iris rubeosis, secondary open-angle glaucoma, and secondary angle-closure glaucoma. Management of neovascular glaucoma focuses on treating retinal ischemia, controlling neovascularization, and reducing intraocular pressure. The aim of treatment is to prevent vision loss through panretinal photocoagulation, intravitreal and intracameral anti-VEGF injections, and glaucoma treatment, including pharmacological therapy and surgical procedures. It is essential to address the underlying disease.
- 29 October 2025
- Published by Termedia Sp. z.o.o. in Ophthalmology
- Vol. 28 (2) , 36-40
Open AccessNeovascular glaucoma
Neovascular glaucoma is an aggressive form of secondary angle-closure glaucoma that can potentially lead to blindness. It is characterized by neovascularization of the iris and the drainage angle. The proliferation of fibrovascular tissue within the drainage angle leads to the formation of peripheral anterior synechiae and an increase in intraocular pressure. Neovascular glaucoma develops as a consequence of ischemia and hypoxia in the posterior segment of the eye. The ischemic retina produces pro-angiogenic factors. The most important factor in the process of neovascularization is vascular endothelial growth factor. The most common underlying causes of neovascular glaucoma are diabetic retinopathy, central retinal vein occlusion, and ocular ischemic syndrome. The course of neovascular glaucoma can be divided into four stages: pre-rubeosis stage, iris rubeosis, secondary open-angle glaucoma, and secondary angle-closure glaucoma. Management of neovascular glaucoma focuses on treating retinal ischemia, controlling neovascularization, and reducing intraocular pressure. The aim of treatment is to prevent vision loss through panretinal photocoagulation, intravitreal and intracameral anti-VEGF injections, and glaucoma treatment, including pharmacological therapy and surgical procedures. It is essential to address the underlying disease.
- Open Access
- 29 October 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11) , 3501
Predictive Value of Bleb Vascularity after Mitomycin C Augmented Trabeculectomy
Background: To evaluate the relationship between bleb vascularity and surgical outcome one year after mitomycin C (MMC) augmented trabeculectomy. Methods: This was a prospective study of 51 eyes of 44 patients after MMC-augmented primary trabeculectomy with follow-up of 12 months. The total vessel area of a bleb was measured with ImageJ software on color photographs of the bleb on day 1 and 14, then months 1, 3, 6 and 12 after trabeculectomy. Blebs were classified clinically as successful (intraocular pressure (IOP) ≤ 18 mmHg and a >30% reduction in IOP without antiglaucoma medications or additional surgical interventions) or failed. Linear regression analysis was performed to determine the correlation of bleb vascularity with IOP and outcome. Results: At 1 year, 40 eyes (78.4%) were classified as successful and 11 eyes (21.6%) as failed. The mean bleb vascularity at 1, 3 and 12 months after surgery was significantly higher in failed blebs (16.31% vs. 13.01%, p = 0.005, 14.93% vs. 10.15%, p = 0.001, 8.99% vs. 6.37%, p = 0.011, respectively). There were no significant differences in mean bleb vascularity at 1 and 14 days postoperatively in successful and failed blebs. The results revealed a significant association between vessel area at 1 and 3 months after trabeculectomy with IOP at 6 months postoperatively (p = 0.005 and p = 0.009, respectively). Conclusions: In this prospective study, we demonstrated a strong relationship between bleb vascularity and the surgical outcomes of trabeculectomy. Vascularity of the filtering bleb during early postoperative period was not correlated with IOP or success of trabeculectomy at one year. Increased bleb vascularity 1, 3 and 12 months after trabeculectomy appears to predict surgical failure at 1 year after trabeculectomy.
- 29 October 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11) , 3501
Open AccessPredictive Value of Bleb Vascularity after Mitomycin C Augmented Trabeculectomy
Background: To evaluate the relationship between bleb vascularity and surgical outcome one year after mitomycin C (MMC) augmented trabeculectomy. Methods: This was a prospective study of 51 eyes of 44 patients after MMC-augmented primary trabeculectomy with follow-up of 12 months. The total vessel area of a bleb was measured with ImageJ software on color photographs of the bleb on day 1 and 14, then months 1, 3, 6 and 12 after trabeculectomy. Blebs were classified clinically as successful (intraocular pressure (IOP) ≤ 18 mmHg and a >30% reduction in IOP without antiglaucoma medications or additional surgical interventions) or failed. Linear regression analysis was performed to determine the correlation of bleb vascularity with IOP and outcome. Results: At 1 year, 40 eyes (78.4%) were classified as successful and 11 eyes (21.6%) as failed. The mean bleb vascularity at 1, 3 and 12 months after surgery was significantly higher in failed blebs (16.31% vs. 13.01%, p = 0.005, 14.93% vs. 10.15%, p = 0.001, 8.99% vs. 6.37%, p = 0.011, respectively). There were no significant differences in mean bleb vascularity at 1 and 14 days postoperatively in successful and failed blebs. The results revealed a significant association between vessel area at 1 and 3 months after trabeculectomy with IOP at 6 months postoperatively (p = 0.005 and p = 0.009, respectively). Conclusions: In this prospective study, we demonstrated a strong relationship between bleb vascularity and the surgical outcomes of trabeculectomy. Vascularity of the filtering bleb during early postoperative period was not correlated with IOP or success of trabeculectomy at one year. Increased bleb vascularity 1, 3 and 12 months after trabeculectomy appears to predict surgical failure at 1 year after trabeculectomy.